2016
DOI: 10.1080/01635581.2016.1115527
|View full text |Cite
|
Sign up to set email alerts
|

Effect of Curcumin Supplementation During Radiotherapy on Oxidative Status of Patients with Prostate Cancer: A Double Blinded, Randomized, Placebo-Controlled Study

Abstract: Curcumin is an antioxidant agent with both radiosensitizing and radioprotective properties. The aim of the present study was to evaluate the effect of curcumin supplementation on oxidative status of patients with prostate cancer who undergo radiotherapy. Forty patients treated with radiotherapy for prostate cancer were randomized to the curcumin (CG, n = 20) or placebo group (PG, n = 20). They received curcumin (total 3 g/day) or placebo during external-beam radiation therapy of up to 74 Gy. Plasma total antio… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
62
0
3

Year Published

2016
2016
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 85 publications
(67 citation statements)
references
References 35 publications
0
62
0
3
Order By: Relevance
“…Curcumin, a polyphenol of plant origin, has numerous molecular effects; in particular, it suppresses the transcription of nuclear factor-κB, and affects the receptors of various growth factors and cell adhesion molecules involved in tumour growth, angiogenesis and metastasis (36). Curcumin has a radioprotective or radiosensitising effect, depending on the dose, and these effects are now being actively studied to support the use of this product as an adjunct therapy for radio and chemotherapy (37). Thus, preparations that contain various polyphenols may be considered as promising adjunct therapies for oncology patients.…”
Section: A Spleenmentioning
confidence: 99%
“…Curcumin, a polyphenol of plant origin, has numerous molecular effects; in particular, it suppresses the transcription of nuclear factor-κB, and affects the receptors of various growth factors and cell adhesion molecules involved in tumour growth, angiogenesis and metastasis (36). Curcumin has a radioprotective or radiosensitising effect, depending on the dose, and these effects are now being actively studied to support the use of this product as an adjunct therapy for radio and chemotherapy (37). Thus, preparations that contain various polyphenols may be considered as promising adjunct therapies for oncology patients.…”
Section: A Spleenmentioning
confidence: 99%
“…Under the treatment with standard chemotherapy protocols, the bioavailable curcuminoid preparation (180 mg/day) for a period of 8weeks as adjuvant therapy in cancer patients with solid tumors can significantly improve quality of life and suppress systemic inflammation (113). In addition, in curcumin (total 3 g/day) with external-beam radiation therapy of up to 74 Gy patients with prostate cancer group, plasma total antioxidant capacity significantly increased and the activity of superoxide dismutase decreased compared with those at baseline (114). The clinical results still support the use of curcumin as an effective cancer preventive agent, particularly, in several colorectal cancer trials (115, 116).…”
Section: The Importance Of Dose In the In Vitro And In Vivo Chemoprevmentioning
confidence: 93%
“…Finally, most of the evidence on the efficacy of curcumin against melanoma and other types of cancer pertains to preclinical studies. Although some clinical evidence exists that favors the benefits of curcumin supplementation in cancer patients, clinical evidence is still scarce and a thorough outcome study is yet to be performed. Hence, clinical proof‐of‐concept investigations are required to verify the translational value of the reported anti‐tumor effects of curcumin in animal and cellular models of cancer.…”
Section: Resultsmentioning
confidence: 99%